(19)
(11) EP 2 251 014 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.01.2014 Bulletin 2014/02

(45) Mention of the grant of the patent:
20.11.2013 Bulletin 2013/47

(21) Application number: 09718009.5

(22) Date of filing: 04.03.2009
(51) International Patent Classification (IPC): 
A61K 31/704(2006.01)
A61K 31/337(2006.01)
A61K 33/24(2006.01)
A61P 35/00(2006.01)
C07J 9/00(2006.01)
 A61K 31/282(2006.01)
A61K 31/7072(2006.01)
A61K 45/06(2006.01)
A61P 43/00(2006.01)
(86) International application number:
PCT/JP2009/000985
(87) International publication number:
WO 2009/110235 (11.09.2009 Gazette 2009/37)

(54)

COMBINATIONS OF AN ANTI-CANCER AGENT AND A CHOLESTANOL DERIVATIVE

KOMBINATIONEN AUS EINEM ANTIKREBSMITTEL UND EINEM CHOLESTANOLDERIVAT

COMBINAISONS CONTENANT UN AGENT ANTI-CANCER ET UN DERIVÉ DU CHOLESTANOL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 05.03.2008 JP 2008055284

(43) Date of publication of application:
17.11.2010 Bulletin 2010/46

(73) Proprietors:
  • Otsuka Pharmaceutical Co., Ltd.
    Tokyo 101-8535 (JP)
  • National University Corporation Gunma University
    Maebashi-shi Gunma 371-8510 (JP)

(72) Inventors:
  • YAZAWA, Shin
    Osaka-shi Osaka 541-0045 (JP)
  • NISHIMURA, Toyo
    Osaka-shi Osaka 541-0045 (JP)
  • ASAO, Takayuki
    Maebashi-shi Gunma 371-0031 (JP)

(74) Representative: Hartz, Nikolai 
Wächtershäuser & Hartz Patentanwaltspartnerschaft Ottostrasse 4
80333 München
80333 München (DE)


(56) References cited: : 
WO-A1-2005/007172
WO-A2-2005/118071
JP-A- 2000 191 685
 WO-A1-2007/026869
JP-A- 11 060 592
   
  • AHMAD FARIED ET AL: "Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer", CANCER SCIENCE, vol. 98, no. 9, 1 September 2007 (2007-09-01), pages 1358-1367, XP55024322, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2007.00563.x
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).